Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications

Hdl Handle:
http://hdl.handle.net/10675.2/648
Title:
Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications
Authors:
Guan, Ruili; Purohit, Sharad; Wang, Hongjie; Bode, Bruce; Reed, John Chip; Steed, R. Dennis; Anderson, Stephen W.; Steed, Leigh; Hopkins, Diane; Xia, Chun; She, Jin-Xiong
Abstract:
Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.; Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay.; Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to patients without any complications (mean=201 ng/ml) (p=3.5x10^-6). Furthermore, mean serum MCP-1 is higher in controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p<10^-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio=0.11, p<10^-33).; Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.
Citation:
PLoS One. 2011 Apr 12; 6(4):e17822
Issue Date:
12-Apr-2011
URI:
http://hdl.handle.net/10675.2/648
DOI:
10.1371/journal.pone.0017822
PubMed ID:
21532752
PubMed Central ID:
PMC3075244
Type:
Article
ISSN:
1932-6203
Appears in Collections:
Center for Biotechnology and Genomic Medicine: Faculty Research and Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGuan, Ruilien_US
dc.contributor.authorPurohit, Sharaden_US
dc.contributor.authorWang, Hongjieen_US
dc.contributor.authorBode, Bruceen_US
dc.contributor.authorReed, John Chipen_US
dc.contributor.authorSteed, R. Dennisen_US
dc.contributor.authorAnderson, Stephen W.en_US
dc.contributor.authorSteed, Leighen_US
dc.contributor.authorHopkins, Dianeen_US
dc.contributor.authorXia, Chunen_US
dc.contributor.authorShe, Jin-Xiongen_US
dc.date.accessioned2012-10-26T16:26:58Z-
dc.date.available2012-10-26T16:26:58Z-
dc.date.issued2011-04-12en_US
dc.identifier.citationPLoS One. 2011 Apr 12; 6(4):e17822en_US
dc.identifier.issn1932-6203en_US
dc.identifier.pmid21532752en_US
dc.identifier.doi10.1371/journal.pone.0017822en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/648-
dc.description.abstractBackground: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent.en_US
dc.description.abstractMethods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay.en_US
dc.description.abstractResults: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to patients without any complications (mean=201 ng/ml) (p=3.5x10^-6). Furthermore, mean serum MCP-1 is higher in controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p<10^-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio=0.11, p<10^-33).en_US
dc.description.abstractConclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.en_US
dc.rightsGuan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectResearch Articleen_US
dc.subjectBiologyen_US
dc.subjectBiochemistryen_US
dc.subjectProteinsen_US
dc.subjectPlasma Proteinsen_US
dc.subjectMedicineen_US
dc.subjectClinical Immunologyen_US
dc.subjectImmune Systemen_US
dc.subjectCytokinesen_US
dc.subjectAutoimmune Diseasesen_US
dc.subjectGenetics of the Immune Systemen_US
dc.subjectEndocrinologyen_US
dc.subjectDiabetic Endocrinologyen_US
dc.subjectDiabetes Mellitus Type 1en_US
dc.titleChemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complicationsen_US
dc.typeArticleen_US
dc.identifier.pmcidPMC3075244en_US
dc.contributor.corporatenameCenter for Biotechnology and Genomic Medicine-
dc.contributor.corporatenameDepartment of Pathology-

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.